Skip to main content
editorial
. 2014 Sep 9;13(4):213–220. doi: 10.5114/pm.2014.44996

Fig. 4.

Fig. 4

Effects of combined oral contraceptive containing dienogest/oestradiol valerate (DNG/E2V) in perimenopausal women. The figure reports the percent variation of bone mineral density (BMD) measured by DXA (Lunar Corporation) in eumenorrhoic, oligomenorrhoic (supplemented with 500 mg calcium a day) and oligomenorrhoic-OC treated perimenopausal women (mean age 49.5 ± 2.1 yr.; n = 25 in each group)